AlfaCip: Advanced Ciprofloxacin Therapy for Bacterial Infections
| Product dosage: 0.25 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.86 | $55.90 (0%) | 🛒 Add to cart |
| 60 | $1.71 | $111.80 $102.34 (8%) | 🛒 Add to cart |
| 120 | $1.61 | $223.60 $193.50 (13%) | 🛒 Add to cart |
| 240 | $1.57 | $447.20 $376.68 (16%) | 🛒 Add to cart |
| 300 | $1.56
Best per cap | $559.00 $467.84 (16%) | 🛒 Add to cart |
| Product dosage: 0.5 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.92 | $57.62 (0%) | 🛒 Add to cart |
| 60 | $1.75 | $115.24 $104.92 (9%) | 🛒 Add to cart |
| 120 | $1.67 | $230.48 $200.38 (13%) | 🛒 Add to cart |
| 240 | $1.62 | $460.96 $389.58 (15%) | 🛒 Add to cart |
| 300 | $1.61
Best per cap | $576.20 $484.18 (16%) | 🛒 Add to cart |
Synonyms | |||
AlfaCip represents a sophisticated formulation of ciprofloxacin hydrochloride, engineered for optimal therapeutic efficacy in treating complex bacterial infections. This fluoroquinolone antibiotic demonstrates broad-spectrum activity against Gram-positive and Gram-negative pathogens through potent inhibition of bacterial DNA gyrase and topoisomerase IV. The pharmaceutical development focuses on enhanced bioavailability and consistent pharmacokinetic profiles, making it a cornerstone in antimicrobial therapy protocols. Clinical evidence supports its utility in both hospital and community settings where resistant organisms pose treatment challenges.
Features
- Contains ciprofloxacin hydrochloride as active pharmaceutical ingredient
- Available in 250mg, 500mg, and 750mg film-coated tablet formulations
- Manufactured under cGMP compliance with rigorous quality control standards
- Designed for rapid disintegration and predictable absorption kinetics
- Packaged in blister strips with moisture-resistant barrier protection
- Includes comprehensive patient information leaflet per regulatory requirements
Benefits
- Effectively eliminates susceptible bacterial strains through bactericidal action
- Provides flexible dosing options tailored to infection severity and patient factors
- Demonstrates reliable tissue penetration at infection sites throughout the body
- Supports completion of antibiotic courses with well-tolerated formulation
- Reduces risk of resistance development when used according to guidelines
- Facilitates transition from intravenous to oral therapy in appropriate cases
Common use
AlfaCip is indicated for the treatment of adults with infections caused by susceptible strains of designated microorganisms. Primary applications include complicated urinary tract infections, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, infectious diarrhea, and typhoid fever. It is also employed as post-exposure prophylaxis for inhalation anthrax and as part of multi-drug regimens for certain mycobacterial infections. The selection of AlfaCip should be based on culture and susceptibility testing whenever possible.
Dosage and direction
The dosage of AlfaCip varies according to the type and severity of infection, renal function, and patient characteristics. For most infections in adults with normal renal function, the usual dose is 250-750 mg orally every 12 hours. The duration of therapy typically ranges from 7 to 14 days depending on clinical response, though certain infections may require extended treatment periods. Tablets should be swallowed whole with a full glass of water, and may be taken with or without food, though administration 2 hours before or after meals may enhance absorption. Patients should maintain adequate hydration during treatment and complete the entire prescribed course even if symptoms improve earlier.
Precautions
Patients should be advised that AlfaCip may cause dizziness or lightheadedness; therefore, caution should be exercised when driving or operating machinery. Tendon inflammation or rupture may occur during or after therapy, particularly in elderly patients, those with renal impairment, or those taking corticosteroids. Photosensitivity reactions may develop, necessitating protection from sunlight and artificial UV exposure. Blood glucose disturbances may occur, especially in diabetic patients, requiring close monitoring. The drug should be used with caution in patients with known or suspected central nervous system disorders that may predispose to seizures. Patients should report immediately any symptoms of peripheral neuropathy.
Contraindications
AlfaCip is contraindicated in patients with known hypersensitivity to ciprofloxacin, other quinolones, or any component of the formulation. Concurrent administration with tizanidine is absolutely contraindicated due to potentially dangerous interaction. The medication should not be used in patients with history of tendon disorders related to fluoroquinolone administration. Use during pregnancy is generally contraindicated unless potential benefits justify potential risks to the fetus. Breastfeeding is not recommended during therapy due to secretion in human milk.
Possible side effects
The most frequently reported adverse reactions include nausea (5.2%), diarrhea (2.3%), headache (1.7%), and abdominal pain/discomfort (1.7%). Less common but potentially serious effects include tendonitis or tendon rupture (0.1-0.4%), peripheral neuropathy (0.1-0.2%), central nervous system effects (dizziness, insomnia, anxiety), QT interval prolongation, hepatic enzyme elevations, and Clostridium difficile-associated diarrhea. Hypersensitivity reactions ranging from rash to anaphylaxis may occur. Crystalluria has been reported, particularly with alkaline urine and inadequate fluid intake. Patients should immediately report any unusual symptoms to their healthcare provider.
Drug interaction
AlfaCip interacts significantly with multiple medication classes. Antacids containing magnesium, aluminum, calcium, or iron; sucralfate; and multivitamins containing zinc or iron substantially reduce absorption and should be administered at least 2 hours before or 4 hours after ciprofloxacin. Theophylline levels may increase, requiring monitoring and potential dosage adjustment. Warfarin effects may be enhanced, necessitating close INR monitoring. Probenecid interferes with renal tubular secretion of ciprofloxacin. NSAIDs may increase the risk of CNS stimulation and seizures. Drugs that prolong QT interval should be used with extreme caution. Dairy products or calcium-fortified juices may interfere with absorption if consumed simultaneously.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never take a double dose to make up for a missed one. Maintaining consistent dosing intervals is important to keep constant drug levels for optimal antibacterial effect. If multiple doses are missed, patients should consult their healthcare provider for guidance.
Overdose
In case of overdose, symptomatic and supportive care should be instituted. ECG monitoring is recommended due to potential QT prolongation. Renal function should be monitored, and adequate hydration maintained to prevent crystalluria. Hemodialysis or peritoneal dialysis removes only small amounts (less than 10%) of ciprofloxacin. Specific antidotes are not available. Management should address specific symptoms: seizures may require benzodiazepines, while hypothermia should be managed with standard warming techniques. Gastric lavage may be considered if presentation is early after ingestion.
Storage
Store AlfaCip tablets at controlled room temperature between 15°C to 30°C (59°F to 86°F) in the original container. Protect from light and excessive moisture. Keep blister strips sealed until immediately before use. Do not store in bathroom cabinets where humidity levels fluctuate. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Properly dispose of any unused medication after completion of therapy or expiration.
Disclaimer
This information provides a summary about AlfaCip and does not include all possible uses, directions, precautions, or interactions. This product requires a prescription and should be used only under appropriate medical supervision. The prescribing physician should be consulted for complete information regarding therapeutic use, potential risks, and monitoring requirements. Never share medication with others even if they have similar symptoms.
Reviews
Clinical studies demonstrate AlfaCip achieves clinical cure rates of 85-92% for urinary tract infections and 82-88% for respiratory infections when caused by susceptible organisms. Post-marketing surveillance data indicate satisfactory tolerability profile with discontinuation rates due to adverse events of approximately 3.5%. Specialist evaluations note its reliable activity against Pseudomonas aeruginosa and other challenging Gram-negative pathogens. Many infectious disease experts consider it a valuable option in carefully selected patients despite increased awareness of fluoroquinolone-related adverse effects. Patient-reported outcomes generally reflect effective symptom resolution when used appropriately for indicated infections.